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The complement system is a fundamental part of the innate immune system, playing a 
crucial role in host defense against various pathogens, such as bacteria, viruses, and fungi. 
Activation of complement results in production of several molecules mediating chemo-
taxis, opsonization, and mast cell degranulation, which can contribute to the elimination 
of pathogenic organisms and inflammation. Furthermore, the complement system also 
has regulating properties in inflammatory and immune responses. Complement activity 
in diseases is rather complex and may involve both aberrant expression of complement 
and genetic deficiencies of complement components or regulators. The skin represents 
an active immune organ with complex interactions between cellular components and 
various mediators. Complement involvement has been associated with several skin 
diseases, such as psoriasis, lupus erythematosus, cutaneous vasculitis, urticaria, and 
bullous dermatoses. Several triggers including auto-antibodies and micro-organisms 
can activate complement, while on the other hand complement deficiencies can con-
tribute to impaired immune complex clearance, leading to disease. This review provides 
an overview of the role of complement in inflammatory skin diseases and discusses 
complement factors as potential new targets for therapeutic intervention.
Keywords: complement, dermatology, skin diseases, innate immunity, psoriasis, hidradenitis suppurativa, lupus 
erythematosus, bullous pemphigoid
iNTRODUCTiON
The Complement System
The complement system consists of a network of more than 50 different plasma and membrane-
associated proteins. It is a part of the innate immune system and plays a key role in host defense 
against pathogens as well as in tissue homeostasis. The complement system can be activated through 
three distinct pathways: the classical, lectin, and alternative pathway (Figure 1). Classical pathway 
activation occurs after binding of the first component C1q to antibody-antigen complexes, cell 
particles, or certain acute phase proteins such as C-reactive protein or serum amyloid P. Once 
the complement activation cascade is initiated, the attached serine proteases C1r and C1s become 
activated. This is followed by cleavage of, respectively, C4 and C2, leading to the formation of a C3 
convertase (C4b2a) that can activate C3 (1). The lectin pathway is activated when mannan binding 
lectin (MBL), ficolins, and/or collectins interact with carbohydrate structures predominantly pre-
sent on invading pathogens. Consequently, this activates MBL-associated serine proteases 1 and 2 
(MASP1 and MASP2), subsequently cleaving C4 and C2. The classical and lectin pathways generate 
FigURe 1 | Schematic overview of the complement system: activation and regulation.
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the shared C3 convertase C4b2a, which in turn generates the 
opsonin C3b and anaphylatoxin C3a through cleavage of native 
C3. In contrast to the classical and lectin pathways, the alterna-
tive pathway is activated by low grade spontaneous hydrolysis of 
systemic native C3 (“C3 tickover”) or via properdin binding to 
certain cell surfaces (e.g., bacteria). Hydrolyzed C3 [C3(H2O)] 
can associate with Factor B (FB), which is subsequently activated 
by Factor D. This results in the formation of a C3 convertase 
(C3H20Bb) that can finally cleave C3. This fluid phase C3 con-
vertase cleaves C3 to generate C3a and C3b. C3b can covalently 
bind to nearby structures and provides the basis for generation 
of the surface bound C3 convertase C3bBb. Alternative pathway 
activation can also be initiated as an amplification loop when 
C3b, generated by either one of the three pathways, is deposited 
on the triggered surface and binds to FB, which also results in 
the formation of the surface bound C3 convertase C3bBb. C3 
convertases can be stabilized by factor P (properdin). C3b, gen-
erated by the classical, lectin, or alternative pathway, combines 
with the C3 convertases to form the C5 convertases (C4b2aC3b 
and C3bBbC3b), initiating the terminal complement cascade. 
C5 convertases cleave C5 into C5b and anaphylatoxin C5a, 
eventually resulting in the assembly of C5b-9 by combining C5b 
with C6-C9. C5b-9 can form channels into the cell membrane 
causing cell lysis. In addition to the capacity to generate C5b-9, 
complement split products iC3b and C3dg are known to have 
immunomodulating functions (1–3).
Several soluble and cell-bound regulators are capable of medi-
ating complement regulation on different levels of the comple-
ment cascade to limit damage to self-cells (Figure 1). C1-esterase 
inhibitor (C1-INH), C4b binding protein (C4BP), FH, FI, 
vitronectin, and clusterin are the soluble regulators. However, 
if complement components still manage to deposit on the cell 
membrane, inactivation of complement can be achieved by cell-
bound regulators. These include decay-accelerating factor (DAF/
CD55), membrane cofactor protein (MCP/CD46), complement 
receptor-1 (CR1), and CD59 (protectin) (4).
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Complement System and the Skin
Plasma complement proteins are predominantly synthesized in the 
liver by hepatocytes, although extrahepatic complement can also 
be produced by other cell types such as endothelial cells, epithelial 
cells, and immune cells. Furthermore, complement receptors and 
membrane regulators can also be synthesized by other types of 
cells, such as leukocytes, fibroblasts, adipocytes, and endothelial 
cells (5). An important role of extrahepatic synthesized comple-
ment components is the protection against micro-organisms and 
inflammation at tissue or organ level.
The skin is the body’s largest organ that serves as an immune 
and physical barrier against pathogenic organisms, irritant, xeno-
biotics, allergens, UV-irradiation, and mechanical injury. The 
epidermis is an active immune organ equipped with immune-
competent cells, including Langerhans cells, keratinocytes, 
dendritic epidermal T-lymphocytes, and melanocytes, of which 
the keratinocyte is the predominant cell type. The dermis harbors 
many immune cells such as dermal dendritic cells (DC) and mast 
cells. Multiple reports have demonstrated that human keratino-
cytes are able to produce several complement proteins including 
complement components C3, C4, and FB of which synthesis can 
be regulated and enhanced by interleukin- 1α (IL-1α), interferon-γ 
(IFN-γ), and tumor necrosis factor-α (TNF-α). Furthermore, 
keratinocytes can also synthesize soluble complement regulators 
such FH and FI, complement receptors CR1, cC1qR, C5aR1, and 
CR2 and cell-bound complement regulator proteins MCP, DAF, 
and CD59. Importantly, IFN-γ can enhance the production of 
FH and FI locally, thereby preventing epidermal damage which 
could be caused by locally produced C3, C4, and FB (6, 7). Besides 
keratinocytes, also melanocytes express cell-bound complement 
regulator proteins DAF, MCP, and CD59, making these cells less 
vulnerable to autologous complement attack. For example in 
vitiligo, melanocytes and keratinocytes seem to express less cell-
bound regulators, which adds to the cells susceptibility to lysis (8). 
Langerhans cells and DC are the antigen-presenting cells, which 
have the capacity to initiate primary immune responses. Human 
DCs are able to produce most of the complement components and 
are also qualified to identify soluble and cell-bound complement 
effector molecules. Interestingly, the functional development of 
DCs depends on complement production and activation. Hence, 
T-cell differentiation can be indirectly determined by comple-
ment, in particular the anaphylatoxins C3a and C5a (5).
The skin is colonized by a diversity of microbes including com-
mensals and potential pathogens. The skin plays an important 
role in restraining the invasion of opportunistic or pathogenic 
organisms. The complement system may partly impact this 
microbial ecosystem by regulating complement C5aR1 signaling. 
Inhibition of C5aR1 signaling results in lower microbial diver-
sity, making the skin less resistant to pathogenic organisms (2). 
Moreover, inhibiting C5aR1 signaling also decreases expression 
of various chemokines, cytokines, anti-microbial peptides, and 
pattern recognition receptors (2). In particular, downregulation 
of IL-12 by complement might impact the differentiation and 
development of T cells (9).
Overall, the complement system forms an important bridge 
between the innate and adaptive immune system. Complement acti-
vation products are known to mediate chemotaxis, opsonization, 
and mast cell degranulation, which can contribute to the elim-
ination of pathogenic organisms. Aberrant expression and gen-
etic deficiencies of complement components or regulators are 
associated with certain skin diseases. Complement activation in 
different skin diseases has experienced a first period of high-level 
attention already in the 1970s and 1980s. However, in the fol-
lowing decades the interest in complement has declined, paral-
leling intensified research into lymphocyte function, adaptive 
immunity, and immunogenetic associations in skin diseases. The 
introduction of immunosuppressive agents targeting the adap-
tive immune system, for example, cyclosporine in the treatment 
of psoriasis, shifted the interest from innate to adaptive. A second 
“wave of attention” in complement occurred after the develop-
ment and introduction of several new complement inhibiting 
agents. These complement inhibitors are now effectively being 
used in clinical practise in several diseases, for example, in the 
treatment of renal disease. The main purpose of this review is to 
provide an overview of the role of complement in inflammatory 
skin diseases and to discuss the rationale and potential targets 
for pharmacological intervention using complement inhibiting 
therapeutics.
PSORiASiS
Psoriasis is a chronic skin disease, affecting approximately 2–4% 
of the Western population. Although the exact etiology of psoria-
sis remains unclear, it is considered a multifactorial disease with 
genetic, environmental, and behavioral factors playing a role in 
the pathogenesis and course of the disease. Psoriasis vulgaris 
(plaque psoriasis) is the most common form of the disease (affect-
ing 70% of the patients) and usually presents as symmetrical 
erythematous papules or plaques covered with thick silvery scales 
located on the extensor side of the elbows and knees, scalp, and 
lumbosacral area. The scales are a consequence of a hyperpro-
liferative epidermis, which is reflected on histology by parakera-
tosis, alternating regular hyperplasia with elongation of the rete 
ridges, loss or absence of the granular layer, and dilated capillaries 
of the papillary dermis (Figure 2). In addition, the epidermis may 
show transepidermal migration of neutrophils, and to a lesser 
extent lymphocytes, to the corneal layer that results in the forma-
tion of Munro microabscesses (10, 11). A Munro microabscess 
is a collection of neutrophils in the stratum corneum and can 
be considered as one of the characteristic histological findings 
of psoriasis. Inflammation in the dermis is characterized by a 
superficial perivascular infiltrate of lymphocytes.
Already in the 1970s and 1980s, several research groups have 
examined the scale extracts from psoriatic lesions, unraveling 
the underlying mechanisms of transepidermal leukocyte migra-
tion, and Munro microabscess formation. It was found that 
psoriatic scales exhibit chemotactic and chemokinetic proper-
ties compared with scales from non-psoriatic patients (12, 13). 
Subsequently, the presence of C3a in the extracts of psoriatic 
scales was demonstrated (14). Deposition of C3b in the presence 
of immunoglobulins in stratum corneum of skin biopsies from 
psoriasis patients suggested activation of the classical pathway of 
complement (15). Furthermore, also C5a was found in psoriatic 
leukotactic factor (PLF) and appeared to be the most potent 
FigURe 2 | Psoriasis vulgaris. Confluent parakeratosis, psoriasiform epidermal hyperplasia [(A), EH], hypogranulosis, and influx of numerous neutrophils  
in the corneal layer [(A), arrow]. (B) Transepidermal migration of neutrophils from the dermis to the corneal layer (arrows).
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chemotactic factor in psoriatic scales. Several subsequent studies 
were able to confirm these findings by monitoring elevated levels 
of anaphylatoxins (C3a, C4a, C5a, C5a des-Arg) in scales of psori-
atic lesions (16–19). Deposition of complement and the presence 
of complement activation products in psoriatic scales might be 
explained by locally produced and activated complement. In 
addition, systemic derived complement components and/or sys-
temic complement activation could also be an important source 
of complement deposition in psoriasis.
Regarding systemic complement activation, sera, and plasma 
from psoriasis patients showed elevated levels of complement 
components, complement split products, and regulator proteins 
including FB, Bb, C3, C3a, C3b, C4, C4a, C4d, C5b-9, C1-INH, 
C4BP, FH, and FI. These results suggest involvement of both clas-
sical and alternative pathways in systemic complement activation 
(20–24). Marley et  al. demonstrated low-circulating properdin 
levels in psoriatic patients, also indicating alternative pathway 
activation (25). Ohkohchi et al. found that, although circulating 
levels of classical complement pathway regulators C1-INH and 
C4BP were slightly increased, marked increase of alternative 
pathway regulator proteins were found and associated with dis-
ease activity and skin involvement (23). Altogether, these findings 
support a prominent role for systemic alternative pathway activa-
tion in psoriasis. However, the most convincing and controlled 
study was performed by Fleming et al., taking into account and 
excluding confounders that could potentially bias results from 
the previously described studies. These included discrepancy in 
the involved pathways, infection, and different types of psoriasis. 
It was found that circulating C5b-9 levels did not correlate with 
the extent and disease activity. More importantly, the absence of 
specific associated components, such as the immune complexes 
C1r-C1s-C1-INH and C3bBbP, in the plasma of psoriasis patients 
with elevated C5b-9 levels is a direct evidence that systemic com-
plement is not activated in psoriasis (20).
Thus, previously cited literature shows that local comple-
ment is activated in psoriatic scales but systemic complement is 
unlikely to be activated in psoriasis. Therefore, it is reasonable to 
assume that complement activation products in the circulation 
originate from spillover of local products into the circulation (26). 
Important questions in this respect are: what are the triggers for 
local complement activation and what is the overall contribution 
of complement activation in the pathogenesis of psoriasis.
There are several hypotheses that might explain the activation 
of complement and the inherent generation of C5a in psoriatic 
scales. Firstly, natural auto-antibodies are directed against carbo-
hydrate antigens in the stratum corneum and this results in IgG, 
C3b, and/or C4b deposition, reflecting classical pathway activation 
(27, 28). However, one study provided evidence that IgG and C3b 
binding to stratum corneum also occurred in other parakeratotic 
lesions such as verruca vulgaris and lichen simplex chronicus. Yet 
these parakeratotic lesions do not evolve into psoriatic lesions, 
suggesting that immunoglobulin binding and complement activa-
tion within the lesional stratum corneum might not be a conse-
quential pathogenic event in psoriasis (15). Secondly, complement 
is activated independent of immunoglobulins via direct cleavage 
of C5 by serine proteinases present in the stratum corneum or 
via alternative pathway activation. The alternative pathway can be 
activated when serum comes in direct contact with the stratum 
corneum after traumatic injury (29, 30). Thirdly, complement is 
activated by microbial products, which is supported by the fact 
that infections can trigger the exacerbation of psoriasis in a much 
higher number of patients than was previously believed (26, 31). 
Lastly, complement is activated in the dermis, pervades into the 
epidermis, causing neutrophils to migrate, and damage epidermal 
cells (32). Although previously cited studies have shown local 
complement activation in psoriatic scales, one should argue 
what is the source of complement in the upper epidermis. In the 
literature, there have been several reports of keratinocytes being a 
rich source of producing complement components including C3, 
FB, FH, and FI. Regarding the terminal complement components 
(C5–C9), a study revealed keratinocytes to express and release 
C7 and C9 (33). Moreover, both TNF-α and IFN-γ have been 
shown to augment the production of C3 by keratinocytes (34). 
Although systemic complement activation is unlikely to play a 
role in psoriasis as previously described, circulating complement 
components could also be a rich source for local activation.
Whatever the cause of complement activation in psoriasis 
might be, it is interesting to speculate about the concept that com-
plement might be one of the initiating factors in the pathogenesis 
of psoriasis. Psoriasis is regarded as an auto-immune disease and 
5Giang et al. Complement System and Skin Diseases
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therefore therapy in psoriasis has mainly focused on targeting 
the adaptive immune system. Clinical and mechanistic stud-
ies are generally conducted in patients with stable plaque type 
psoriasis (psoriasis vulgaris), characterized by an adaptive T-cell 
predominant phenotype. However, to study the pathogenesis of 
psoriasis, one has to take into account the stage, activity, and type 
of psoriasis. Early psoriatic lesions are characterized clinically by 
pinpoint papules, papulopustular lesions or as pustular psoriasis. 
Histologically, early psoriatic lesion show influx of neutrophils 
in the dermal papillae, transepidermal migration of neutrophils 
(squirting papillae), dermal capillary activation, tortuous dilata-
tion, and angiogenesis (35–37). Importantly, this stage is charac-
terized by predominance of neutrophils, in particular in pustular 
psoriasis. The pathogenesis is auto-inflammatory and driven by 
innate immune activation, in contrast to lymphocyte predomi-
nant auto-immune activation in stable plaque type psoriasis. In 
the complex immunopathology of psoriasis, it is thought that 
during innate immune activation, plasmacytoid dendritic cells 
(pDCs) are activated together with IL-1β and TNF-α producing 
keratinocytes in response to dendritic Toll-like receptor activation 
by DNA (LL-37). In this initiating phase, neutrophil recruitment 
has mainly been attributed to the release of IL-1β and TNF-α. 
However, anaphylatoxin C5a is the most potent chemo-attractant 
for various inflammatory cells including neutrophils, monocytes, 
and macrophages. It was hypothesized that in the earliest psori-
atic neutrophil predominant lesions, complement is activated in 
the stratum corneum, C5a is released which can activate immune 
cells and keratinocytes. C5a can migrate to the dermal microvas-
culature, activating endothelial cells, and mast cell degranulation, 
which results in capillary tortuous dilatation, so characteristic 
for (early) psoriasis. To investigate this hypothesis, Tagami et al. 
analyzed the effect of intradermal PLF (mainly consisting of 
C5a) injections in guinea pigs. Light microscopy of skin biopsies 
revealed features reminiscent of actual psoriasis lesions and com-
parable with injection of C5a in vivo in healthy human volunteers 
(38). These histological features included dense infiltration of 
neutrophils in the dermis followed by increased epidermopoiesis, 
epidermal proliferation, and degeneration. In contrast, PLF/C5a 
did not induce proliferation or influenced the viability of cultured 
human epidermal cells (32). These results suggest that PLF/C5a 
requires specific circumstances necessary to exert its effect on 
skin, most probably the presence of neutrophils from the circula-
tion. Altogether, besides IL-1β and TNF-α, C5a is likely to play a 
role in the early neutrophil predominant and auto-inflammatory 
phase of psoriasis. Following auto-inflammatory initiation, the 
response is shifted toward auto-immune activation including 
activation of the IL-23/IL-17 axis characteristic for stable plaque-
type psoriasis. However, more and more evidence points toward 
bimodal immune activation in psoriasis. Alternating waves of 
auto-inflammatory bursts of neutrophils coexist with T-cell 
driven auto-immune activation (37). Complement might be one 
of these factors linking innate auto-inflammatory and adaptive 
auto-immune responses in psoriasis. Two recent studies have 
provided evidence supporting this theory. Treatment of mice 
with siRNA targeting C3 reduced skin disease in a mouse model 
of psoriasis (39). Furthermore, using the imiquimod-induced 
model of psoriasis, it was found that C3 deficient mice showed 
significantly reduced levels of IL-1β, TNF-α, IL-17a, and IL-23 in 
the skin and draining lymph nodes and decreased infiltration of 
neutrophils (40). These studies clearly show a link between com-
plement activation and activation of IL-23/IL-17 axis of adaptive 
immunity. Clinical studies targeting complement activation 
might investigate whether flares of psoriasis can be prevented by 
targeting innate immunity instead of treating adaptive immune 
activation in well-established psoriatic plaques.
ACNe vULgARiS AND HiDRADeNiTiS 
SUPPURATivA (HS)
Acne vulgaris
Acne vulgaris is a common cutaneous disorder and its pathogen-
esis is multifactorial including genetic, infectious, and hormonal 
factors. The distribution of the skin lesions in acne vulgaris 
reflects that of sebaceous glands. Patients present with comedones 
predominantly on the face, nose, forehead, and chest (sebaceous 
areas). Light microscopy reveals open and closed comedones, 
which are a result of excessive sebum secretion, hyperkeratosis 
of the sebaceous duct, and follicular infundibulum, subsequently 
followed by hair follicle dilatation. Excessive dilatation of the fol-
licular infundibulum eventually results in rupture of the epithe-
lial layer. Besides distension, epithelial damage is also attributed 
to overgrowth of Propionibacterium acnes (P. acnes) in the hair 
follicle lumen. P. acnes is an anaerobic bacterium and a habitual 
follicular resident. Although data exist implicating P. acnes in the 
initiation of follicular distension and obstruction, the bacterium 
is primarily involved in the subsequent inflammatory response 
of the hair follicle. Once ruptured, secondary inflammatory 
changes occur, such as granulomatous inflammation in response 
to epithelial fragments, and chronic-active inflammation (41, 42).
Today, it is still not known what is the sequence of events that is 
responsible for evolution of a non-inflamed into an inflamed acne 
lesion. Evidence exists that complement activation could be one 
of the primary triggers in this inflammatory response in acne. In 
1966, Puhvel et al. revealed that high levels of complement fixing 
antibodies are present in patients with severe acne compared 
with patients with mild or no acne (43). Scott et al. analyzed non-
inflamed (white- and black heads) and inflamed (papules and 
nodules) acne lesions. The most frequent finding was perivascular 
granular and/or linear pilosebaceous basement membrane zone 
(of affected units) deposition of C3b in both non- and inflamed 
acne lesions (44). Similar findings were reported by Dahl et al. 
in early acne lesions (12). In non-inflamed acne lesions, C3b 
deposition preceded influx of mononuclear cells while inflamed 
lesions showed both C3b deposition as well as mononuclear 
inflammation. Kligman et  al. observed that microscopic hair 
follicle rupture precedes clinical inflammation. In uninvolved 
skin of patients with acne sometimes microcomedones are seen 
with early inflammatory changes, with migration of neutrophils 
into intact follicular epithelium. In a later stage, the follicular 
epithelium becomes spongiotic and small foci of neutrophils can 
be found in the hair follicle lumen (45). These findings suggest 
that in the early stages of acne chemotactic factors are released 
from the intact hair follicle to recruit neutrophils. Complement 
FigURe 3 | Hidradenitis suppurativa. Sinus tracts [(A), arrow], active inflammation, and rupture [(B), asterisks] of the follicular epithelium with “floating” hair 
fragments [(B), arrow]. Subsequently, a secondary inflammatory response is induced with influx of numerous neutrophils [(C), arrows] and granulomatous  
foreign body reaction with giant cells [(C), asterisks].
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activation products, in particular C5a, is the most likely factor 
involved in the chemokinesis of neutrophils that initiates the con-
version of a non-inflamed into an inflamed lesion. Interestingly, 
C3b deposition was almost exclusively found without concurrent 
immunoglobulin or C1q deposition, suggesting that the alterna-
tive pathway might be primarily involved in the development 
of acne vulgaris. A candidate triggering factor for complement 
activation might be P. acnes, since bacteria are well known to 
activate complement. It has been shown that both the alternative 
and classical complement pathways can be activated in normal 
human serum upon interaction with comedonal contents as well 
as P. acnes (46–49). Another possibility is the direct activation of 
the alternative pathway by the stratum corneum (30). Both Dahl 
et al. and Scott et al. only found isolated granular C3b deposi-
tion or granular C3b with immunoglobulin deposition along the 
dermo-epidermal junction in a few biopsies. This could hypo-
thetically represent immune complex formation with P. acnes 
and possibly subsequent classical pathway activation (12, 44). 
Whatever the trigger or route of complement activation might 
be, C5a is released acting as a potent chemokinetic factor in the 
recruitment of neutrophils. Therefore, it is plausible to hypoth-
esize that the increased influx of neutrophils in acne vulgaris is, 
at least in part, dependent on complement activation and may 
therefore be amenable to complement inhibiting therapies.
Hidradenitis Suppurativa
Hidradenitis suppurativa (synonym: acne inversa) is a severe 
inflammatory follicular skin disease causing severe patient 
discomfort and psychosocial burden. HS is a common, yet unrec-
ognized and underdiagnosed disease with a prevalence of 1–4% 
of the European population. Patients present in the acute stage 
with painful inflamed nodules (boils) in the inverse apocrine 
bearing regions of the body such as the groin and axilla. In a late 
stage, sinus tract formation occurs with formation of abscesses 
and scarring. Importantly, systemic therapy with immunosup-
pressive agents (systemic corticosteroids, dapsone, and cyclo-
sporin) has been investigated in the past decade and has shown 
limited efficacy.
Although the exact pathogenesis of HS still has yet to be 
unraveled, different theories have been proposed during the 
last decade. In general, it is believed that HS is a multifactorial 
disease in which genetic, environmental factors (such as smok-
ing, microbial colonization, and obesity) and the immune system 
interact. Follicular occlusion is thought to be the primary event in 
HS and is caused by follicular infundibular epithelial hyperplasia 
and hyperkeratosis. It is hypothesized that this could be a result 
of microbial overgrowth due to a deficient follicular skin immune 
system or, in contrast, an overactive immune system that reacts 
to normal skin flora. Eventually, follicular plugging and occlu-
sion will result in hair follicle rupture. Upon rupture, classical 
histological features are observed as seen in a ruptured epidermal 
cyst or comedone such as granulomatous inflammation on kera-
tin fibers and chronic inflammation (Figure 3). Although such 
material is rapidly cleared in ruptured epidermal/acne cysts, the 
inflammatory response in HS persists, leading to chronicity with 
formation of sinus tracts and scarring (50–52).
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Although “HS” is a misnomer since involvement of sweat 
glands is not a central event in the pathogenesis of HS, HS is 
indeed characterized by suppuration with deep abscess forma-
tion. Although not classified as a neutrophilic dermatosis, influx 
of numerous neutrophils is a characteristic histological feature of 
HS. However, it is uncertain whether this is an early or late event 
in the pathogenesis of this disease. The inflammatory response in 
HS is characterized by increased levels of IL-1β and TNF-α, both 
in (peri)lesional skin biopsies as well as circulating levels in HS 
patients (53). The important role of these cytokines is illustrated 
with the clinical improvement observed after treatment with 
TNF-α antagonists infliximab and adalimumab (54). Recruitment 
of neutrophils has been mainly attributed to TNF-α and IL-1β, 
however, the role of complement activation has only recently been 
studied. Blok et al. found induction of complement pathway genes 
in lesional HS skin biopsies, indicating involvement of the com-
plement system in this disease (55). An open label phase 2 study 
is currently underway with the C5a inhibitor IFX-1 in patients 
with moderate to severe HS (NCT 03001622). Recent results from 
this study demonstrated systemic complement activation in HS 
patients reflected by increased circulating levels of C5a and C5b-9 
(56). Furthermore, increased C5a serum levels in HS patients 
were able to activate neutrophils, thereby contributing to HS 
symptoms. Up to 83%, HS clinical response rate was achieved at 
the endpoint of anti-C5a treatment in this phase 2 clinical study. 
Thus, targeting the C5a–C5aR axis may represent a promising 
therapeutic strategy for HS patients, most probably via inhibition 
of systemic neutrophil activation. Besides systemic activation, 
also local complement could potentially be activated in HS since 
commensal follicular skin bacteria, similar to acne vulgaris, might 
function as pathogen-associated molecular patterns that can acti-
vate classical and alternative complement pathways. Furthermore 
and in a later stage after hair follicle rupture, cellular fragments 
might function as danger-associated molecular patterns, which 
can also activate complement. Whether complement activation, 
and aberrant immune activation in general in HS, is a primary 
or secondary event to an initial hair follicle process remains to 
be investigated.
SYSTeMiC AND CUTANeOUS LUPUS 
eRYTHeMATOSUS (Le)
Lupus erythematosus is a heterogeneous auto-immune disease, 
which is characterized by the presence of elevated immune 
complexes, high titers of auto-antibodies against nuclear and 
cytoplasmic components and consumption of complement 
components. Deposition of immune complexes within various 
organs causes tissue damage, producing a broad spectrum of 
clinical manifestations ranging from systemic to solely cutaneous 
lesions. Epidemiological studies have estimated the prevalence 
of systemic LE (SLE) to be around 0.2–0.7% occurring predomi-
nantly in patients older than 40 years of age, with a female/male 
ratio of 9:1 (57). The cause of SLE is multifactorial with genetic, 
environmental, and hormonal contributions, also integrated in 
the American College of Rheumatology (ACR) guideline for 
SLE. This guideline requires at least four of the 11 clinical and 
laboratory components to be present before diagnosing SLE. 
Whereas the revised classification Systemic Lupus International 
Collaborating Clinics requires four components with one clinical 
and one immunologic item (58). Studies have shown that skin 
involvement will eventually develop in about 70% of patients with 
SLE, although primary cutaneous LE (CLE) mainly develops in 
the absence of systemic features. The probability of progression 
from CLE to SLE is approximately 20% (59). There are a few sub-
sets in which CLE can be classified: acute LE, subacute (SCLE), 
and chronic cutaneous LE (CCLE), of which CCLE can be further 
subdivided into discoid LE, LE profundus, LE tumidus, chilblain 
lupus, and bullous LE (60).
Literature over the years suggests that the pathogenesis of 
SLE and CLE might share common features, along with the 
developmental consequences of genetic, environmental factors, 
and immune dysregulation. Several haplotypes and certain alleles 
of the major histocompatibility complex (MHC) have shown 
association with different subtypes of CLE. From a mechanistic 
point of view, MHC polymorphisms may lead to an increase of 
auto-reactive T-lymphocytes mediated by a selection error in 
the thymus (61). Furthermore, a panel of single nucleotide poly-
morphisms (SNPs) has been shown to be associated with CLE, 
including TYK2, IRF5, and CTLA4. These polymorphisms may 
have an influence on the IFN cytokine signaling (62).
A well-known trigger of CLE is ultraviolet light (UVL), also 
one of the ACR criteria of SLE, included as photosensitivity. 
Firstly, UVL can penetrate through different layers of the skin, 
causing acute inflammation as well as damage to the DNA, 
thereby inducing keratinocyte apoptosis (63). Accumulation of 
apoptotic material due to decreased clearance can result in the 
formation of immune complexes, which in turn can enhance 
the IFN-α production by pDCs. IFN-α is an important cytokine 
in the recruitment of Th1 and cytotoxic T cells (62). Secondly, 
UVL directly increases the production of TNF-α, interferons, 
and several interleukins of keratinocytes and dermal fibroblasts. 
These cytokines are responsible for the infiltration of leukocytes 
in skin biopsies of CLE (61).
Numerous auto-antibodies, resulting from impaired clearance 
of immune complexes, can be found in patients with CLE. The 
role of auto-antibodies in CLE is not completely understood, 
although some auto-antibodies have been found to be useful 
indicators in the prognosis of the disease. Patients with anti-RNP, 
anti-Sm, and anti-aPL antibodies are closely associated with high 
prevalence of malar rash, while patients with only anti-Ro/SSA anti-
bodies demonstrated to have an increased risk for nephritis (62).
Besides genetic variation in certain MHC class I and II alleles, 
congenital deficiencies of classical complement pathway com-
ponents C1q, C1r, C1s, C4, and C2 are strongly associated with 
the development of SLE (62). In addition, a homozygous SNP of 
the C1QA gene appears to be highly associated with SCLE (64). 
Boeckler et  al. were the first to demonstrate a high prevalence 
of partial deficiency of C2, C4 and combined C2/C4 in patients 
with CLE (65). Furthermore, C4 copy number variation of C4A 
and C4B genes is also associated with the risk of SLE (extensively 
reviewed elsewhere) (66). Two concepts could potentially explain 
the development of SLE in patients deficient in classical pathway 
components. Firstly, early classical pathway components are 
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involved in the induction of immune tolerance in germinal centers 
of lymph nodes. It is well known that CD35/CR1 and CD21/CR2 
on follicular DC bind and present complement factors to virgin 
B-cells in order to differentiate self from non-self B-cells. More 
specifically, it was demonstrated that CD21, CD35, or C4 defic-
ient mice resulted in high levels of anti-nuclear antibodies and 
severe lupus-like disease (67). Therefore, complement deficiency 
results in the breach of self-tolerance and subsequently the devel-
opment of SLE. Secondly, complement deficiency results to the 
inability of efficiently clearing apoptotic cells/debris and could 
render them to become auto-antigens, induce auto-antibody for-
mation and thereby SLE. Most research has been performed on 
the latter concept, in particular the role of C1q deficiency in LE. 
There are three sets of findings that link C1q to the development 
of SLE. Firstly, congenital C1q deficiency is the strongest genetic 
risk factor known for the development of SLE (68). Secondly and 
paradoxically, circulating levels of C1q are strongly decreased in 
SLE as a result of classical complement activation. Thirdly, anti-
C1q antibodies can be found in approximately 33% of the patients 
with SLE and usually coincides with classical pathway activation 
(69, 70).
One of the main functions of C1q is to act as an opsonin to 
stimulate removal of apoptotic cell fragments. C1q can directly 
bind to the surface of apoptotic keratinocytes through its globu-
lar heads, which results in the formation of C3 convertases. This 
is followed by cleavage of C3 and the release anaphylatoxin C3a 
and the opsonin C3b which results in the clearance of apoptotic 
cells by phagocytosis (71). Furthermore, the collagenous region 
of C1q can bind to the calreticulin/CD91 complex, which is 
expressed on the surface of phagocytes. This binding enhances 
phagocytosis, leading to ingestion of C1q coated apoptotic cells 
(72). C1q deficiency therefore directly interferes with the clear-
ance of apoptotic cell debris. Although this is interesting from a 
mechanistic point of view, most SLE patients are C1q sufficient 
and therefore other mechanisms underlie the impaired clearance 
of apoptotic debris in SLE. Impaired clearance of apoptotic cells 
could lead to secondary necrosis, causing disintegration, and 
high expression of potential auto-antigens on the surface of 
apoptotic bodies and blebs (73). This induces the production of 
auto-antibodies against these “lupus auto-antigens” by B-cells. 
In turn, auto-antibody-antigen complexes bind C1q thereby 
activating the classical pathway of complement (74). Together 
with classical pathway activation as a result of C1q bound to 
apoptotic blebs, this explains the paradox that SLE patient show 
strong ongoing complement activation with low and sometimes 
undetectable serum complement levels (secondary hypocomple-
mentemia). Furthermore, it is thought that prolonged exposure 
of C1q bound to the surface of apoptotic blebs could become 
antigenic due to impaired clearance that consequently induces 
production of auto-antibodies to C1q (75). Recent studies have 
demonstrated that anti-C1q specifically interacts with C1q bound 
to early apoptotic cells and not to C1q bound to immunoglobu-
lins or immune complexes. Antigen-C1q-anti-C1q complexes 
induce classical pathway activation also causing secondary 
hypocomplementemia. Besides, this results in interference 
of the uptake of apoptotic cells and impaired C1q-dependent 
phagocytosis (76, 77).
The deposition of auto-antibody-antigen complexes can be 
visualized in skin biopsies by immunofluorescence in the 
so-called “lupus band test,” demonstrable as granular or linear 
deposits of IgG, C3b and occasionally IgA and IgM along the 
dermo-epidermal junction. The lupus band test can be applied 
to differentiate SLE from CLE and also as a prognostic parameter 
for patients with LE. A positive reaction can be observed in both 
lesional as well as non-lesional skin in SLE. However, in CLE only 
lesional skin shows a positive lupus band test. More importantly, 
sun-exposed skin biopsies of healthy individuals may also exhibit 
a positive lupus band test; therefore, it is essential to perform direct 
immunofluoresence on sun-protected skin (78). Interestingly, also 
MBL deposition was recently found in lesional skin of patients 
with SLE, indicating involvement of the lectin pathway (79).
Lastly, there seems to be no clear difference in the role of comp-
lement between SLE and CLE. The complement system, especially 
C1q, appears to play a crucial role in the pathogenesis of SLE and 
CLE. The absence of functional C1q can lead to impaired clear-
ance of apoptotic cells, resulting in expression of auto-antigens, 
and induction of auto-antibody generation. Furthermore, C1q 
can eventually bind to these surface blebs stimulating the produc-
tion of auto-antibodies to C1q itself. Despite the increased knowl-
edge concerning the pathogenesis of SLE, it remains a complex 
disease in which multiple mechanisms are of significance.
CUTANeOUS SMALL veSSeL  
vASCULiTiS (CSvv)
Cutaneous small vessel vasculitis is defined as inflammation of 
the postcapillary venules in the skin. CSVV without presence 
of systemic vasculitis is currently named as single organ CSVV, 
according to the updated Chapel Hill Nomenclature for Vasculitis 
(80). There are also other subtypes of CSVV with systemic involve-
ment such as anti-neutrophil cytoplasmic antibodies (ANCA)-
associated vasculitis and cryoglobulinemic vasculitis. CSVV is 
the most common type of vasculitis with an incidence of 15 per 
million. The majority of the patients are adults with a slight pref-
erence for females (81). Over the years, numerous studies have 
revealed multiple factors taking part in the development of CSVV. 
The disease seems to be associated with drugs, infections, and 
systemic disorders such as SLE, RA, or malignancy. However, in 
many patients there is no identifiable cause and in these cases 
CSVV is then considered as a primary idiopathic entity (82, 83).
The classical presentation of CSVV usually occurs 7–14 days 
after exposure to a triggering agent. Palpable purpura are the hall-
mark of CSVV, and appear as red-purple discolorations on the 
skin varying from 2 to 5 mm in size. However, CSVV presents as 
many clinical variants, depending on the severity and duration of 
the disease including urticaria, pustules, erosions, and ulcers (81).
The histopathologic pattern observed in CSVV is leukocyto-
clastic vasculitis (LCV), which is characterized by a superficial 
infiltrate surrounding the postcapillary venules predominantly 
composed of neutrophils, leukocytoclasis, endothelial swelling, 
extravasation of erythrocytes, and eventually fibrinoid necrosis 
(Figure 4) (82). Moreover, the presence of eosinophils can be an 
indicator of drug-induced CSVV.
FigURe 4 | Small vessel leucocytoclastic vasculitis. The section shows all 
features of leucocytoclastic vasculitis. A mixed inflammatory cell population 
surrounding the postcapillary venules of the superficial dermis. The infiltrate 
consists of neutrophils with nuclear dust (dashed arrows) and shows high 
affinity for the vessels. Features of vascular injury are shown including 
fibrinoid necrosis (asterisks) and erytrocyt extravasation (solid arrows).
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activation of neutrophils and upregulation of several adhesion 
molecules (E-selectin, ICAM-1, and V-CAM) on the surface of 
endothelial cells, allowing neutrophils, and other inflammatory 
cells to migrate from the circulation into the site of inflammation 
(87). Activated neutrophils can secrete reactive oxygen species 
and also dysregulate the expression of serine proteinases elastase 
and cathepsin G, which eventually leads to endothelium damage 
(88). Additionally, decreased tissue plasminogen activator (t-PA) 
in response to released cytokines due to vascular damage leads to 
abnormal fibrinolysis and may eventually result in fibrin deposi-
tion as reflected on histology (89). Under physiologic conditions, 
various regulators secreted or/and expressed by endothelial 
cells maintain control of complement activation. These include 
C1-INH, FH, FI, vitronectin, clusterin, and CD55/DAF (90). 
Interestingly, Boom et  al. observed that DAF expression on 
endothelial cells of cutaneous vasculitis was almost completely 
absent, while DAF expression on intraluminal erythrocytes was 
unaffected. Expression of DAF on the surface can restrain assembly 
of the terminal cascade by binding to C3b, and thereby interfering 
with the C5 convertases. The authors suggest that the absence of 
DAF might be the consequence of local downregulation of DAF 
synthesis and might play an important role in the pathogenesis of 
CSVV (91). However, there is only sparse literature available about 
potent downregulators of DAF.
In aggregate, the complement system appears to be associated 
with the development of CSVV. The interaction between comple-
ment components and activation products, and the endothelial 
cells seem to play an essential role in the pro-inflammatory 
response seen in CSVV. Activation of classical pathway of com-
plement has been recognized in CSVV, regarding to the immune 
complex-mediated process. In particular, the effects of C5a and 
MAC on endothelial cells and neutrophils may eventually lead to 
structural and functional damage of the endothelium resulting 
in CSVV.
URTiCARiA AND URTiCARiAL 
vASCULiTiS (Uv)
Urticaria
Urticaria is widely held to be one of the most common skin dis-
eases, affecting up to approximately 20% of the population during 
lifetime. Urticarial lesions are characteristically pruritic, edema-
tous, erythematous papules, or wheals often with pale centers, 
which can merge into larger plaques and usually resolve within 
24 h. Urticaria consists of a wide spectrum ranging from local-
ized wheals to widespread recurrent wheals with angioedema. 
Coexisting episodes of angioedema appear to be present in 
approximately 40% of patients with urticaria (92). Angioedema 
can be characterized as edema in the deep dermal layer and 
subcutaneous or submucosal tissues. Acute urticaria is defined 
by disease duration of less than 6 weeks, whereas recurrent urti-
carial lesions persisting for a period beyond 6 weeks is defined as 
chronic urticaria (CU). CU can be further divided into chronic 
inducible urticaria and chronic spontaneous urticaria (CSU). 
Inducible urticaria is caused by a response to external triggers, 
including cold, heat, allergens, sunlight, sweat, and pressure (92). 
Accumulating evidence has indicated that the complement 
system plays a significant role in the pathogenesis of CSVV. 
Immunofluorescence studies have supported this hypothesis by 
demonstrating deposits of immunoglobulins of IgM- and IgG 
classes, C3c and fibrinogen in, and around dermal vessel walls 
in LCV. Grunwald et  al. demonstrate these immunoreactants 
in skin biopsies of early, mature, and healing stages of vasculi-
tis (84). Detection of vascular IgA deposition is defined for 
Henoch–Schonlein purpura (85). Vascular immunoglobulin and 
complement were also detected in non-lesional skin, suggesting 
that deposition of these immunoreactants is a primary event, and 
not secondary to endothelial damage (81). In addition, Dauchel 
and colleagues reported that C3d and C5b-9 were significantly 
increased in plasma of patients with LCV compared with controls, 
whereas C3, C1q, C2, C4, and FB were within normal ranges. 
These findings indicate local as well as systemic complement 
activation in patients with LCV. Moreover, the increased level of 
C3d and C5b-9 has been shown to correlate with vasculitis activ-
ity. Interestingly, circulating C3d and C5b-9 levels did correlate 
with disease activity but not with the intensity of perivascular 
cutaneous depositions, suggesting that C3d and C5b-9 plasma 
levels are caused by systemic complement activation instead of 
passive diffusion from cutaneous lesions into the circulation (86).
The most widely accepted concept of the pathogenesis is 
deposition of immune complexes in postcapillary venules, with 
inflammation occurring after complement activation. As men-
tioned previously, multiple etiologies can trigger the formation of 
circulating immune complexes. These consist of foreign antigens 
and antibodies in slight excess of antigen, and therefore easily 
get trapped and subsequently deposited in small vessels. These 
immune complexes lead to activation of the complement cascade 
via the classical pathway. Among the activated complement 
products, C5a and C5b-9 seem to be mainly responsible for the 
endothelial damage observed in CSVV (82, 83). C5a induces 
FigURe 5 | Urticaria. Dermal edema [solid arrows in (A,B)] and a sparse superficial predominantly perivascular and interstitial infiltrate of lymphocytes and 
eosinophils without signs of vasculitis (dashed arrow).
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CSU is mainly idiopathic, although researchers have identified a 
subpopulation with an auto-immune etiology. The histopathol-
ogy of an urticarial lesion mostly involves changes in the upper 
dermis, consisting of mild dermal edema, and sparse perivascular 
and interstitial mixed inflammatory infiltrate composed of a vari-
able number of lymphocytes, monocytes, mast cells, eosinophils, 
and neutrophils (Figure 5) (93). The pathophysiological events 
in the formation of wheals involve activation of dermal mast 
cells and basophils by various triggers, including anaphylatoxins 
C3a and C5a, and also physical stimuli. It is well established 
that binding of antigen to antigen-specific IgE on mast cells and 
basophils activates and degranulates these inflammatory cells 
(type 1 hypersensitivity reaction). The most important active sub-
stance in urticaria is histamine. Histamine induces vasodilation, 
increases vascular permeability, and stimulation of sensory nerve 
endings leading to pain or itching. Other important mediators 
such as TNF-α, leukotrienes, platelet-activator, and prostaglandin 
D2 may also promote an inflammatory response (94). The exact 
trigger or cause of histamine release has not been identified in 
most patients with CSU. Evidence of an auto-immune etiology 
in approximately 45% of patients has been presented. Patients 
with CSU have shown to possess circulating IgG auto-antibodies 
directed against the α subunit of IgE (anti-FcεR1α) and IgE recep-
tor in their sera, corresponding to a type 2 hypersensitivity reaction 
(95). Additionally, increased frequency of thyroid dysfunction 
and thyroid auto-antibodies (anti-microsomal peroxidase and 
anti-thyroidglobulin) are found in patients with CSU (96).
IgG auto-antibodies bound to IgE or IgE receptor on mast cells 
results in the activation of complement via the classical pathway 
followed by generation of C5a and C5b-9. Subsequently, C5a can 
mediate mast cell activation via C5aR1 ligation with subsequent 
degranulation and release of mediators, resulting in urticarial 
wheals (97, 98). Accumulated evidence has shown that comple-
ment is involved in degranulation of mast cells and basophils in 
some patients with CSU (97). Firstly, one study demonstrated 
that heat inactivation of serum complement of patients with 
CU, decreased the capacity of serum to release histamine from 
basophils (99). Ferrer and colleagues found that unless serum 
containing C2 and C5 was added to IgG derived from CU 
sera, histamine is not released from mast cells, implicating that 
activation of the classical complement pathway is required for 
mast cell degranulation (100). In parallel with early studies, the 
presence of complement, especially C5a, had a role in augmenting 
IgG-dependent histamine release from basophils (101). Although 
the immune reaction in urticaria is regarded as a type 1 and type 
2 hypersensitivity reaction, also local complement deposition can 
be found in about one-third of chronic urticarial lesions without 
signs of systemic activation, suggesting a type 3 hypersensitivity 
reaction as well (102–105).
Urticarial vasculitis
Urticarial vasculitis is a relatively uncommon disease with an 
estimated prevalence of 5%, occurring more often in women. 
Clinical cutaneous manifestations of UV consist of erythematous 
urticarial papules and plaques that last 24–72 h with a tendency 
to heal with purpura or hyperpigmentation. Patients with UV can 
be classified as normocomplementemic UV (NUV) or hypoc-
omplementemic UV (HUV) depending on serum complement 
levels. Although NUV is mostly idiopathic, HUV is associated 
with a more severe form of disease and can indicate an underly-
ing disease like SLE or hypocomplementemic urticarial vasculitis 
syndrome (HUVS) (106). HUVS is characterized by urticaria with 
hypocomplementemia, arthralgia/arthritis, glomerulonephritis, 
recurrent abdominal pain, and obstructive lung disease (107). 
According to retrospective observations, there seems to be no 
transition among UV subtypes (108). Histopathologically, lesions 
of UV reveal combined features of urticaria with superimposed 
vascular damage. In contrast to LCV, vascular damage in UV is 
more subtle with endothelial activation, sparse karyorrhexis, and 
focal fibrinoid necrosis present in only the minority of cases (109).
Various reports support the hypothesis that UV is an immune 
complex-mediated disease. Deposits of immunoglobulins, com-
plement, and/or fibrinogen in the vessel walls are often observed by 
immunofluorescence in patients with UV. Additionally, imm une 
complexes are also regularly detected in the blood circulation of 
patients with UV. There are numerous etiologies that can trigger the 
formation of immune complexes in UV, including auto-antibodies, 
infections, and medications. Formation of immune complexes 
leads to activation of the complement cascade via the classical 
pathway and subsequently generation of C3a, C5a, and C5b-9. 
FigURe 6 | Bullous pemphigoid. Subepidermal blistering [solid arrows in (A,B)] and influx of inflammatory cells including eosinophils and neutrophils in the  
dermis [solid arrow (C)] and blister cavity [dashed arrows (C)]. In (C) also deposition of fibrin is noted (asterisks).
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Release of C5a can lead to a chain of events, including activation 
of neutrophils, mast cell degranulation, and eosinophil degranula-
tion, which in turn can result in endothelial damage (106).
Wisnieski et al. were the first to suggest that the pathogenesis 
of HUVS might involve abnormal genetic background (110). 
Subsequently, one study found that genetic mutations in the 
DNASE1L3 gene are associated with a familial form of HUVS and 
SLE. The protein encoded by this gene functions as endonuclease, 
which is possibly responsible for the removal of DNA during 
apoptosis (111). This finding supports the link between SLE and 
HUVS. Another similar feature in both diseases is the presence 
of auto-antibodies against C1q that can be detected in 100% of 
the patients with HUVS and in approximately one-third of the 
patients with SLE (69, 108). Anti-C1q antibodies bind to the 
collagenous region of C1q and usually coincide with decreased 
levels of classical pathway complement components as a result of 
complement activation. Additionally, decreased levels of CH50, 
C2, and C4 were also found in patients with HUVS (106). These 
findings implicate that complement might contribute to the 
pathogenesis of HUVS.
To summarize, UV consist of a wide spectrum of cutaneous, 
systemic features ranging from urticaria with mild vasculitis 
to systemic vasculitis combined with hypocomplementemia. 
Classical activation of complement is involved in the pathogen-
esis of UV and HUVS.
BULLOUS PeMPHigOiD (BP)
In this section, we will review the role of complement in the 
most common auto-immune bullous dermatosis, BP. Although 
complement has also been shown to be involved in the pathogen-
esis of other auto-immune bullous dermatoses, such as mucous 
membrane pemphigoid, epidermolysis bullosa acquisita, derma-
titis herpetiformis, and bullous systemic LE, the reader is referred 
elsewhere to more detailed publications on this topic (112–114).
Bullous pemphigoid is the most frequently encountered 
acquired auto-immune blistering disease most commonly affect-
ing the elderly. Clinically, patients present with tense pruritic 
dome-shaped fluid filled blisters measuring up to several centim-
eters in diameter. The most commonly recognized BP antigens 
are BP180 (BPAG2) and BP230 (BPAG1) and less frequently, anti-
bodies can be found against plectins and LAD1. Most antibodies 
in BP are directed against the NC16A domain of BP180, which is a 
major non-collagenous extracellular antigenic site. Separation in 
BP occurs at the level of the lamina lucida. A skin biopsy from an 
established blister reveals a subepidermal blister, often accompa-
nied by a superficial dermal infiltrate of lymphocytes, eosinophils, 
neutrophils, mast cells, and monocytes/macrophages (Figure 6). 
These inflammatory cells are also found in the blister fluid in 
the cell-rich variant of BP. Immunofluorescence demonstrates 
specific linear IgG and/or C3b deposition along the basement 
membrane zone. Although deposition of complement fragments 
such as C3c and C1q is routinely used for diagnostic reasons, 
activation of the complement system has also been shown to play 
a crucial role in the development of disease.
Complement components and activation fragments including 
C1q, C3, C3c, C3d, C4, C4d, C5, C5b-9, FB, FH, and properdin 
have been found at the basement membrane zone and blister 
fluid in BP. These findings indicate involvement of both classical 
and alternative pathways in the pathogenesis of BP (115–117). 
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Recently, complement split products C3d and C4d have been 
shown to be deposited along the basement membrane zone in 
formalin fixed paraffin embedded tissue and might be a potential 
substitute for direct immunofluorescence in the near future 
(118–122).
Liu et al. developed an experimental mouse model of BP using 
a rabbit antibody against murine BP180NC14A, a homolog of 
human BP180NC16A, which is, however, very poorly conserved 
in murine protein. This antibody was passively transferred in 
neonatal mice and developed a subepidermal blistering disease 
closely mimicking clinical BP. This experimental model of BP 
has demonstrated a critical role for complement activation in 
BP. Mice deficient of C5 or depleted of complement by cobra 
venom factor showed no clinical or histological evidence of BP in 
contrast to wild-type (WT) or complement sufficient mice. Also, 
injection of F(ab’)2 fragments prepared from the pathogenic rab-
bit anti-murine BP180 did not show induction of BP, indicating 
a crucial role for the IgG Fc portion in BP. It is the Fc portion 
of antibody that expresses antigen-binding sites for C1q, thereby 
initiating classical complement activation (123). Using the same 
BP model, C4 deficient and WT mice pretreated with anti-mC1q 
were resistant to develop BP, also strongly indicating a crucial role 
for classical complement activation in BP. However, FB deficient 
mice developed delayed and less intense blisters, indicating that 
also the alternative pathway is involved in BP, probably acting 
in concert with classical pathway activation via the amplification 
loop (124, 125). The complement-mediated development of BP 
appeared to be dependent on mast cells and neutrophils. Mice 
depleted of circulating neutrophils did not develop BP after 
injection of anti-mBP180. Reconstitution with C5a or injection 
with neutrophil chemokine IL-8 in C5 deficient mice regained 
susceptibility to BP (126). These findings indicate that neutrophil 
recruitment in BP is C5a dependent. However, mice deficient 
in mast cells or C5aR1 deficient mast cells failed to develop BP, 
despite the activation of complement and in the presence of 
neutrophils. The passive transfer model exhibits extensive mast 
cell degranulation, preceding neutrophil infiltration, and sub-
epidermal blistering. It was found that complement-dependent 
chemokinesis of neutrophils is, at least in part, dependent on 
mast cell degranulation via C5aR1 (124, 127).
Although interesting, it is questionable whether this mice 
model can be easily translated to the human situation since 
BP180NC14a is poorly preserved in mice. Therefore, a human-
ized mice model was developed in which mouse BP180NC14A 
was replaced with the homologous human BP180NC16A epitope 
cluster region. Mice injected with anti-human BP180NC16A 
subsequently development BP (128). A similar model was 
developed by Nishie et al. introducing the human COL17 cDNA 
transgene into Col17-null mice (129). Importantly, the previous 
findings of complement-dependent development of BP were 
confirmed (128).
Notably, although complement plays an important role in 
the pathogenesis of BP, more and more evidence emerges that 
also complement-independent mechanisms exist. Several groups 
have shown direct pathogenic effects of auto-antibodies leading 
to depletion of COL17 in keratinocytes and contributing to skin 
fragility in a complement-independent manner (130–132).
Most of the previously cited studies were performed in animal 
or in  vitro models, making interpretation of the data limited. 
However, in a large cohort (n = 300) patient study, Romeijn et al. 
have shown that in the majority of BP skin biopsies, complement 
deposition could be demonstrated. More interestingly, deposition 
of complement was related to clinical and serological disease 
activity strengthening the crucial role of complement in this 
disease (133).
COMPLeMeNT iNHiBiTiNg STRATegieS 
iN SKiN DiSeASeS
For years, many attempts in producing complement-specific drugs 
have been made with limited success. The main challenge in creat-
ing complement-specific drugs has been to discover the balance 
between sufficient blocking of complement activity in order to 
prevent local tissue damage and preserving the protection of this 
system. As outlined in the current review, clinical and experimen-
tal studies have demonstrated variable roles of complement in the 
pathogenesis of skin diseases. The findings and proposed triggers 
for complement activation in different skin diseases are summa-
rized in Table 1. With the impending recognition of neutrophil 
driven auto-inflammatory diseases, IL-1β and TNF-α inhibitors 
have now been proven beneficial for the treatment of specific 
auto-inflammatory diseases such as the use of adalimumab in the 
treatment of HS (54). The successful use of these agents is primar-
ily based on the inhibition of neutrophil chemotaxis. As described 
previously, C5a acts as a potent recruiter of neutrophils by binding 
to C5aR1 expressed primarily by neutrophils. Moreover, C5a can 
trigger increased vascular permeability on endothelial cells and 
activate the adaptive immune system. Therapeutic intervention 
in C5a–C5aR axis could therefore be a promising target for the 
treatment of neutrophil driven skin diseases such as psoriasis and 
HS as well as other neutrophilic dermatoses. Selective neutraliza-
tion of the C5a–C5aR interaction offers opportunities to inhibit 
complement activation without interfering with membrane 
attack complex formation and thereby the defensive potential of 
complement. A decade ago, C5aR antagonist PMX53 has already 
been evaluated and trialed in psoriasis with initial encouraging 
results. Orally administered cyclic peptidomimetic PMX-53 was 
tested in a phase 1b/2a trial in 10 patients with psoriasis and posi-
tive results in many disease measures were obtained. However, 
unfortunately, this drug has a very short half-life of only 70 min 
which severely limits its use in clinical practice (134). Besides 
psoriasis, intervention in C5a–C5aR axis has very recently been 
shown to beneficial in the treatment of HS. Blockade of C5a by an 
anti-C5a antibody demonstrated up to 83% HS clinical response 
rate at the endpoint of anti-C5a treatment in a phase 2 clinical 
study, indicating the importance of complement in this disease 
(NCT03001622). Furthermore, a promising new therapeutic 
agent is a small molecule C5aR inhibitor CCX168 (Avacopan). 
The drug can be orally administered, shows a relatively long half-
life, has shown limited side effects and promising results in other 
neutrophil driven diseases, for example, in ANCA-associated 
vasculitis (135). These therapeutic agents are preferred over the 
use of Eculizumab (Soliris) which is a recombinant humanized 
TABLe 1 | Overview of complement in skin diseases and the proposed triggers of complement activation.
Skin 
disease
Species System Findings related to complement Proposed triggers of complement  
activation and/or results
Reference
Psoriasis Human Scale extracts Elevated:
C3a, C4a, C5a, C5a-des-Arg
1. Natural anti-SC antibodies
2. C5 cleavage by serine proteases in SC
3. Microbial products
4. Alternative pathway activation after trauma
Tagami et al. (14, 32)
Ohkohchi et al. (17)
Schröder et al. (18)
Takematsu et al. (19)
Mrowietz et al. (16)
Human Skin biopsies Deposition:
C3b
IgG, IgM, IgG deposition Weiss et al. (15)
Human Serum Elevated:
FB, Bb, C3, C3a, C3b, C4, C4a, C4d, 
C5b-9, C1-INH, C4bBp, FH, FI
Decreased: properdin
Normal:
C3bBb, C1s-C1-INH
Systemic complement is not activated based  
on normal circulating C3bBb and C1s-C1-INH 
complexes (20)
Fleming et al. (20)
Kapp et al. (21)
Ohkohchi et al. (22, 23)
Rosenberg et al. (24)
Marley et al. (25)
Mice IMQ psoriasis 
model, C3−/−
Elevated:
C3 gene expression in WT mice  
after IMQ treatment
Trigger: unknown
Results: protection against development  
of psoriatic phenotype in C3−/− mice
Giacomassi et al. (40)
Acne 
vulgaris
Human Skin biopsies C3b deposition 1. P. Acnes
2. Natural anti-SC antibodies
3. Immune complexes
Scott et al. (44)
Dahl et al. (12)
HS Human Skin biopsies Gene induction of complement pathways Trigger: unknown Blok et al. (55)
Human Serum Elevated:
C5a, C5b-9
PAMPs and DAMPS Kanni et al. (56)
LE Human Genome Congenital deficiency of C1q,  
C1r, C1s, C4, C2.
C4 copy number variation
1. Breach of self-tolerance and auto-antibody formation
2. Inefficient clearing of apoptotic cells/debris
Racila et al. (64)
Boeckler et al. (65)
Chen JY et al. (66)
Human Serum Elevated:
anti-C1q auto-antibodies
Immune complexes, (anti-C1q) auto-antibodies Prodeus et al. (67)
Antes et al. (69)
Hoekzema et al. (70)
CSVV Human Skin biopsies C3c deposition in vessel wall Immune complexes Grunwald et al. (84)
Human Serum Elevated:
C3d, C5b-9
Immune complexes Dauchel et al. (86)
CU Human Serum Complement-dependent histamine  
release from basophils and mast cells
Type 2 hypersensitivity reaction: auto-antibodies  
against IgE-FcεR1α and IgE receptor
Zweiman et al. (99)
Ferrer et al. (100)
UV Human Serum Elevated:
Anti-C1q auto-antibodies
Hypocomplementemia
(Anti-C1q) auto-antibodies, immune complexes Wisnieski et al. (108)
BP Human Skin biopsies
Blister fluid
Deposition:
Linear basement membrane deposition 
of C1q, C3b, C3c, C3d, C4, C4d, C5, 
C5b-9, FB, FH, properdin
Anti-BP180 and BP230 auto-antibodies Dahl et al. (115)
Jordon et al. (116, 117)
Chandler et al. (118)
Kassaby et al. (119)
Magro et al. (120)
Pfaltz et al. (121)
Villani et al. (122)
Mice C4−/−
C5−/−
FB−/−
Anti-mC1q
CVF depletion
Linear basement membrane C3  
deposition in WT animals
Mechanism: anti-BP180 and BP230 auto-antibodies 
→classical pathway activation, alternative pathway 
activation (amplification loop)
Results in complement −/− mice: protection  
against development of BP
Liu et al. (123)
Heimbach et al. (124)
Nelson et al. (125)
Liu et al. (128)
Nishie et al. (129)
SC, stratum corneum; IMQ, imiquimod; HS, hidradenitis suppurativa; PAMPs, pathogen-associated molecular patterns; DAMPs, danger-associated molecular patterns; LE, lupus 
erythematosus; CSVV, cutaneous small vessel vasculitis; CU, chronic urticaria; UV, urticarial vasculitis; BP, bullous pemphigoid.
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monoclonal antibody directed against C5. Eculizumab intercepts 
the complement cascade at the terminal effector pathway by bind-
ing tightly to C5 and preventing cleavage to C5b. Consequently, 
this suppresses the formation of the C5b-9, increasing susceptibil-
ity to infection (136).
Besides therapeutic intervention in C5a–C5aR axis in auto-
inflammatory diseases, intervention in complement activation is 
likely to be beneficial in BP. This review discussed several experi-
mental mouse studies of BP that demonstrated a crucial role of 
complement activation in this auto-immune bullous disease. 
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Noteworthy, currently two trials with complement inhibitors are 
ongoing in BP: TNT-009 is a monoclonal antibody against C1s 
(NCT02502903) while coversin targets C5 and leukotriene B4 
(http://adisinsight.springer.com/trials/700284185).
Altogether, intervention in C5a–C5aR axis and the inherent 
inhibition of neutrophil recruitment might be the most interest-
ing treatment for complement-mediated inflammatory skin 
diseases.
CONCLUSiON
The complement system represents far more than the originally 
thought function as a non-specific defense mechanism against 
micro-organisms. By virtue of extensive murine model studies 
and genome-wide association studies, our knowledge regarding 
the functions and hidden connections of complement has greatly 
expanded. Besides the protective role of complement, improper 
regulated activation of complement can lead to extensive tis-
sue damage. Local and systemic complement activation has 
been demonstrated in several skin diseases; however, whether 
complement activation has pathogenic significance in different 
skin diseases remains to be investigated. Although not all trig-
gers of complement activation are fully elucidated in different 
skin diseases, antibody, and immune complex deposition play 
an important role in (classical) complement activation. However, 
earlier and more recent experimental studies using mice deficient 
in complement components have shown involvement of com-
plement in the pathogenesis of BP and experimental psoriasis. 
Furthermore, preliminary results of a phase IIa clinical study in 
HS shows promising results using a monoclonal anti-C5a anti-
body. These result indicate that complement mediates, at least in 
part, inflammatory skin diseases, in particular neutrophil driven 
diseases. Therefore, inhibition of neutrophil recruitment through 
intervention in the C5a–C5aR axis might be the most interesting 
target of intervention in inflammatory skin diseases.
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